Skin Therapy Letter

Back to Skin Therapy Letter Home Page Link to DermWebat UBC
Comments or suggestions? Subscription Information
Index • Volume 2 • Part 1 of 2
  • Articles are indexed by drug names, trade-names (marked ®), and disease terms. Bold entries refer to major references.
Drug name
Issue: Page Issue: Page Issue: Page
Abelcet®
2: 6
Accusite®
1: 6
Acitretin®
2: 6 6: 6
Acne vulgaris
1: 4 2: 1 3: 1,6
4: 1 4: 6 6: 6
Acyclovir
1: 1 3: 5 4: 3
5: 2 6: 1
Aldactone®
2: 3
Aldara®
4: 6
Allegra®
1: 6
Allergic rhinitis
1: 6 3: 6
Amlexanox paste
3: 6
Amoxicillin/ clavulanic acid
6: 6
Amphotericin B
2: 6
Androcur
2: 3
Androgenetic alopecia
2: 3
Anthralin
2: 2 2: 5
Anti-acne drugs
2: 1 2: 6 3: 6
4:6 5: 6 6: 6
Antiallergic drugs
1: 6 4: 6
Anti-androgens
2: 3
Antibiotics
6: 6
Anticonvulsants
4: 4 5: 2
Antifungals
2: 6 3: 6 4: 6
5: 6 6: 6
Antipsoriatics
1: 6 2: 6 3: 6
4: 6 5: 6 6: 6
Antivirals
2: 6 4: 6
Aphthasol®
3: 6
Aphthous ulcers
3: 6
Apligraf®
5: 1 5: 6 6: 2
Aspergillosis
2: 6
Astemizole
3: 4
Atopic dermatitis
4: 2
Augmentin®
6: 6
Avirax®
1: 2
Avita®
4: 6
Avobenzone
5: 4
Barrier function
4: 2
Bentoquatam®
1: 3 1: 6
Benzamycin gel
2: 1
Betamethasone 17 valerate
2: 5
Benzoyl peroxide
2: 1
Borrelia burgdorferi
3: 6
Bravavir®
1: 6
Butenafine HCl 1% Cream
2: 6 3: 6
Calcipotriene
2: 5
Calcipotriene solution
4: 6
Calcipotriol
1: 6 2: 5
Candidiasis
4: 6
Capsaicin
4: 4 5: 2 5: 5
Carbamazepine
4: 4
Ceftin®
3: 6
Cefuroxime axetil
3: 6
Chlorhexidine
6: 2
Clindamycin
2: 1
Clobetasol scalp solution
2: 5
Coal tar with sal. acid in petrol.
2: 5
Coal tar shampoos
6: 3
Comedones
2: 1
Contact dermatitis
1: 3
Corticosteroids
2: 5 5: 2
Cosmeceuticals
4: 2
Cosmetic Hair techniques
2: 4
Crinohermal®
2: 3
Crixivan®
3: 4 6: 6
Cutivate cream®
6: 6
Cyproterone
2: 3
Cystic acne
2: 1
Cytokines
4: 6
Cytotoxic agents
6: 3
Dakin's Solution
6: 2
Dandruff
6: 4
Daunorubicin / daunoxome®
6: 6
Delavirdine
5: 6
Denavir®
2: 6 6: 1
Dermagraft TC®
4: 6 5: 1
Dermasof®
1: 5
Derma 20®
5: 6
Desipramine
4: 4
Desogestril
3: 1
Diabetes mellitus
6: 6
Diane®
2: 3
Dianette®
3: 2
Dimethyl sulfoxide (DMSO)
5: 5
Dovonex® cream
1: 6
Dovonex® scalp solution
1: 6
Drug Update
last page of each issue
Dry Skin
4: 2
Emollients
4: 2
Epiderm®
1: 5
Epilaser®
4: 6
Epivir®
3: 4
Erythromycin
1: 4 2: 1
Erythromy. & benzoyl perox. gel
2: 1
Ethyl chloride spray
5: 5
Famciclovir (Famvir® )
1: 2 3: 5 4: 3
5: 2
Female hair loss
2: 3
Fexofenadine® HCl
1: 6
Finasteride
2: 4
5 alpha reductase inhibitors
2: 4
Fluorouracil epinephrine gel
1: 6
Fluticasone proprionate
6: 6
Foscarnet cream
3: 5
Genital herpes
1: 1 1: 6
Genital warts
1: 6
Gestodene®
3: 1
Glucocorticoid drugs
6: 6
Glylorin™
4: 2
Griseofulvin
6: 5
Grenz rays
2: 5
Hair dyes
2: 4
Hair growth stimulant
3: 6
Hair transplantation
2: 4 2: 6
Hand dermatitis
4: 5
Head & Shoulders Shampoo®
6: 3
Hemolytic anemia
6: 6
Hepatitis B & C
3: 4
Herpes labialis
2: 6 6: 1
Herpes simplex virus
3: 2 6: 2
Herpes zoster
1: 2 1: 6 4: 3
Hirsutism
2: 3
HIV exposure
3: 3
HIV percutaneous exposure
3: 2
(HSE) Human skin equivalent
5: 1 5: 6 6: 2
Hydration
1: 5
Hyperandrogenism
2: 3
Hyperglycemia
6: 6
Hyperpigmentation
3: 1
Hypertrophic scars
1: 5
Ichthyosiform erythroderma
  (non-bullous, congenital)
4: 2
Idiopathic chronic urticaria
3: 6
Idoxuridine
5: 5
Imiquimod cream
4: 6
Indinavar
3: 4 6: 6
Integra Artificial Skin®
5: 1
Intralesional corticosteroids
2: 5
Itraconazole cyclodextrin solution
4: 6
Itraconazole pulse
2: 6
Ivermectin
2: 6
Ivy Block®
1: 3 1: 6
Keloids
1: 5
Keratolytics
2: 5
Ketoconazole shampoo
6: 4 6: 6
Klaron®
3: 6
Proceed to Part 2 of 2...
EDITOR: Stuart Maddin Associate Editor: David I. McLean INTERNET EDITOR: Harvey Lui PRINCIPAL MEDICAL WRITER: Susan Kingsley Manuscript Editor: Rodger Hall Editorial Advisory Board: Kenneth A. Arndt, Beth Israel Hospital & Harvard Medical School, Boston; Wilma Fowler Bergfeld, Cleveland Clinic, Cleveland; Jan D. Bos, University of Amsterdam, Amsterdam; Enno Christophers, Universitäts-Hautklinik, Kiel; Hugo Degreef, Catholic University, Leuven; Richard L. Dobson, Medical University of South Carolina, Charleston; Boni E. Elewski, Case Western Reserve University, Cleveland; Barbara A. Gilchrest, Boston University School of Medicine, Boston; W. Andrew D. Griffiths, St. Johns Institute of Dermatology, London; Vincent C.Y. Ho, University of British Columbia, Vancouver; James J. Leyden, University of Pennsylvania, Philadelphia; Howard I. Maibach, University of California Hospital, San Francisco; Larry E. Millikan, Tulane University Medical Center, Louisiana; Takeji Nishikawa, Keio University School of Medicine, Tokyo; Constantin E. Orfanos, Freie Universitäts Berlin, Universitätsklinikum Benjamin Franklin, Berlin; Stephen L. Sacks, Viridae Clinic Sciences, Vancouver; Alan R. Shalita, SUNY Health Sciences Center, Brooklyn; Stephen K. Tyring, University of Texas Medical Branch, Galveston; John Voorhees, University of Michigan, Ann Arbor; Klaus Wolff, University of Vienna, Vienna
Skin Therapy Letter®. (ISSN 1201-5989) Copyright 1997 by International Skin Therapy Newsletter Inc. All rights reserved. Reproduction in whole or in part by any process in whole or in part is strictly forbidden without prior consent of the publisher in writing.
Published six times yearly by International Skin Therapy Newsletter Inc., 835 West Tenth Avenue, Vancouver, British Columbia, Canada V5Z 4E8. Tel: (604) 874-6112. Fax: (604) 873-9919. Annual subscription: Canadian $85 individual; $155 institutional (GST included). US $60 individual; $110 institutional. Outside North America: US$80 individual; $130 institutional. Quotes on multiple subscriptions and student rates supplied upon request.
Skin Therapy Letter Editor: Dr. Stuart Maddin Index to Volume 2
Return to Top